Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open indications; last session of the month and quarter

September 29, 2017 8:16am

Companies will soon be on a reporting parade to show their “stuff”: spending and cash positions to justify present and future development

Preview RMi's morning call. You’d be reading this if you were a SUBSCRIBER!

If you had been right as many times as I have been in these many months of 2017 as a SUBSCRIBER you would know when to get in and out or get back in again!

It’s called premium content for a reason: I report the truth in “our” universe!

A critical pre-market indication ahead of “our” universe’s open!

Lower open expected

Dow futures are DOWN -0.06% (13 point) and NASDAQ futures are UP +0.13% (7.755 points)

U.S. stock futures struggled to push higher on Friday, but the “street” remained on track for monthly and quarterly gains as investors looked ahead to inflation data and a reading on consumer sentiment.

European stocks moved around the flat line as investors digested fresh data releases.

Asian shares finished the quarter on a largely positive note as the greenback nursed its wounds after slipping overnight. Markets also digested a raft of data out of Japan.

Data docket: personal income, consumer spending and core inflation at 8:30 a.m. Eastern Time. All the reports are for August. At 9:45 a.m., the Chicago purchasing managers index for September is out, followed by consumer sentiment at 10 a.m. for the same month. On the Fed docket, Philadelphia Fed President Patrick Harker will give a speech at 11 a.m. Eastern on the economic outlook as well as on fintech at a conference at his regional bank.

Issues that affect the trading day: Traders are trying to find their footing after a week marked by hawkish comments from Federal Reserve Chairwoman Janet Yellen and the long-awaited announcement on tax reform from the Trump administration.

The cell therapy sector closed POSITIVE on Thursday and Wednesday; NEGATIVE on Tuesday, Monday and last Friday.

The cell therapy sector’s record over the last 5 sessions (of 43 covered companies):

· Thursday closed POSITIVE with 14 decliners, 24 advancers and 5 flats;

· Wednesday closed POSITIVE with 13 decliners, 30 advancers and 0 flats;

· Tuesday closed NEGATIVE with 23 decliners, 17 advancers and 3 flats;

· Monday closed NEGATIVE with 23 decliners, 16 advancers and 4 flats;

· Last Friday closed NEGATIVE with 20 decliners, 18 advancers and 5 flat;

Henry ’omics:

From Thursday night’s closing bell post “… this dip needed to be bought as the month and quarter count down … Risks are repeatedly opinionated to the upside and skewered on the downside.

It's TIME step-back and watch ...

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?

Watch list:

The iShares Nasdaq Biotechnology (IBB) closed up +0.14% on Thursday and is NOT indicating in Friday’s pre-market yet was POSITIVE +0.03% in the aftermarket;
The SPDR S&P Biotech ETF (XBI) closed Thursday up +1.67% and is NOT indicating in Friday’s pre-market% yet was positive +0.08% in the aftermarket;
The Health Care Select Sector SPDR ETF (XLV) closed down -0.09% on Thursday and NOT indicating in Friday’s pre-open;
The iShares Russell 2000 (IWM) closed up +0.28% on Thursday and is indicating a POSITIVE +0.05% in Friday’s pre-open

Companies in my headlights:

I’ve said what I seen this month and will refrain on this last session that will settle in October.

The well is empty …

I don’t see October as a good month for sector equities yet, it will be measured in part by how many companies try to raise capital before the end of the year – and quite a few … NEED … those “continuation” dollars!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.